Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Arena Pharmaceuticals has reported total revenues of $3.26m for the second quarter ended 30 June 2011, compared to $2.46m for the same period in 2010.
Subscribe to our email newsletter
Arena’s net loss was $22.91m, or $0.16 loss per diluted share, compared to net loss of $28.76m, or $0.28 loss per diluted share, for the same period in 2010.
For the six months ended 30 June 2011, the company reported total revenues of $7.18m, compared to $4.97m for the same period in 2010.
The company has reported net loss of $62.81m or 0.49 loss per diluted share for the six months ended 30 June 2011, as compared to $60.03m or $0.60 loss per diluted share for the same period in 2010.
Arena president and CEO Jack Lief said they view the results from the Pathology Working Group’s re-adjudication and the CSF study as important steps toward our planned response to the lorcaserin complete response letter.